Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk
Niels W C J
NW
Kröger
Nicolaus
N
Hegenbart
Ute
U
Corradini
Paolo
P
San Miguel
Jesus F
JF
Goldschmidt
Hartmut
H
Perez-Simon
Jose A
JA
Zijlmans
Mark
M
Raymakers
Reinier A
RA
Montefusco
Vittorio
V
Ayuk
Francis A
FA
van Oers
Marinus H J
MH
Nagler
Arnon
A
Verdonck
Leo F
LF
Lokhorst
Henk M
HM
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D017710:Lymphocyte Transfusion; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D011719:Pyrazines / Q000008:administration & dosage*; D012074:Remission Induction; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage*; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib